How many drugs treat Malignant tumor of ovary?

Drug Landscape tracks 10 marketed treatments for Malignant tumor of ovary (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/malignant-tumor-of-ovary.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Malignant tumor of ovary — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Malignant tumor of ovary (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant tumor of ovary, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zejula	niraparib	GSK	Poly(ADP-Ribose) Polymerase Inhibitor	Poly [ADP-ribose] polymerase 2	2017-01-01
Yondelis	TRABECTEDIN	Janssen Prods	Alkylating Drug [EPC]	Proto-oncogene tyrosine-protein kinase Src	2015-01-01
Lynparza	olaparib	AstraZeneca	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	Poly [ADP-ribose] polymerase 2	2014-01-01
Gemzar	Gemcitabine Hydrochloride	Accord Hlthcare	Nucleoside metabolic inhibitor	Ribonucleotide reductase; DNA incorporation	1996-01-01
Nogitecan	topotecan	Novartis	topotecan	ATP-binding cassette sub-family G member 2	1996-01-01
Gemzar	gemcitabine	Accord Hlthcare	Nucleoside Metabolic Inhibitor	DNA polymerase (alpha/delta/epsilon)	1996-01-01
Taxol	nab-paclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Taxol	paclitaxel	Pfizer	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Hexalen	ALTRETAMINE	Eisai	Alkylating Drug	Cytochrome P450 1A2	1990-01-01
Paraplatin	Carboplatin	MYLAN SEIYAKU Ltd	Platinum-containing alkylating agent	DNA	1989-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 6 drugs in Malignant tumor of ovary
Accord Hlthcare · 2 drugs in Malignant tumor of ovary
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in Malignant tumor of ovary
AstraZeneca · 1 drug in Malignant tumor of ovary
GSK · 1 drug in Malignant tumor of ovary
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · 1 drug in Malignant tumor of ovary
Chong Kun Dang · 1 drug in Malignant tumor of ovary
Chipscreen Biosciences, Ltd. · 1 drug in Malignant tumor of ovary
Eisai · 1 drug in Malignant tumor of ovary
French Innovative Leukemia Organisation · 1 drug in Malignant tumor of ovary
Apotex · 1 drug in Malignant tumor of ovary
ARCAGY/ GINECO GROUP · 1 drug in Malignant tumor of ovary

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant tumor of ovary:

Cite this brief

Drug Landscape (2026). Malignant tumor of ovary — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-tumor-of-ovary. Accessed 2026-06-10.

Malignant tumor of ovary full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing